参考文献/References:
[1] Pivonello R,Isidori AM,De Martino MC,et al.Complications of Cushing's syndrome: state of the art[J]. Lancet Diabetes Endocrinol,2016,4(7):611-629.DOI:10.1016/S2213-8587(16)00086-3.
[2] Clayton RN,Jones PW,Reulen RC,et al.Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study[J].Lancet Diabetes Endocrinol,2016,4(7):569-576. DOI:10.1016/S2213-8587(16)30005-5.
[3] van Haalen FM,Broersen LH,Jorgensen JO,et al. Management of endocrine disease: mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis[J].Eur J Endocrinol,2015,172(4):R143-R149.DOI:10.1530/EJE-14-0556.
[4] Petersenn S,Beckers A,Ferone D,et al.Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence[J].Eur J Endocrinol,2015,172(6):R227-R239. DOI:10.1530/EJE-14-0883.
[5] Alexandraki KI,Kaltsas GA,Isidori AM,et al.Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study[J].Eur J Endocrinol,2013,168(4):639-648.DOI:10.1530/EJE-12-0921.
[6] Molitch ME.Diagnosis and treatment of pituitary adenomas: a review[J].JAMA,2017,317(5):516-524.DOI:10.1001/jama.2016.19699.
[7] Sbiera S,Deutschbein T,Weigand I,et al.The new molecular landscape of Cushing's disease[J].Trends Endocrinol Metab,2015,26(10):573-583.DOI:10.1016/j.tem.2015.08.003.
[8] Alwan HA,van Leeuwen JE.UBPY-mediated epidermal growth factor receptor(EGFR)de-ubiquitination promotes EGFR degradation[J].J Biol Chem,2007,282(3):1658-1669.
[9] Ma ZY,Song ZJ,Chen JH,et al.Recurrent gain-of-function USP8 mutations in Cushing's disease[J].Cell Res,2015,25(3):306-317.DOI:10.1038/cr.2015.20.
[10] Reincke M,Sbiera S,Hayakawa A,et al.Mutations in the deubiquitinase gene USP8 cause Cushing's disease[J].Nat Genet,2015,47(1):31-38.DOI:10.1038/ng.3166.
[11] Huang C,Shi Y,Zhao Y.USP8 mutation in Cushing's disease[J].Oncotarget,2015,6(21):18240-18241.DOI:10.18632/oncotarget.4856.
[12] Faucz FR,Tirosh A,Tatsi C,et al.Somatic USP8 gene mutations are a common cause of rediatric Cushing disease[J].J Clin Endocrinol Metab,2017,102(8):2836-2843.DOI:10.1210/jc.2017-00161.
[13] Hollenberg SM,Weinberger C,Ong ES,et al.Primary structure and expression of a functional human glucocorticoid receptor cDNA[J].Nature,1985,318(6047):635-641.
[14] Edman K,Hosseini A,Bjursell MK,et al.Ligand binding mechanism in steroid receptors: from conserved plasticity to differential evolutionary constraints[J].Structure,2015,23(12):2280-2290.DOI:10.1016/j.str.2015.09.012.
[15] Riebold M,Kozany C,Freiburger L,et al.A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease[J].Nat Med,2015,21(3):276-280.DOI:10.1038/nm.3776.
[16] Charmandari E,Chrousos GP,Kino T.Identification of natural human glucocorticoid receptor(hGR)mutations or polymorphisms and their functional consequences at the hormone-receptor interaction level[J].Methods Mol Biol,2009,590:33-60.DOI:10.1007/978-1-60327-378-7_3.
[17] Hurt DE,Suzuki S,Mayama T,et al.Structural analysis on the pathologic mutant glucocorticoid receptor ligand-binding domains[J].Mol Endocrinol,2016,30(2):173-188.DOI:10.1210/me.2015-1177.
[18] Vitellius G,Fagart J,Delemer B,et al.Three novel heterozygous point mutations of NR3C1 causing glucocorticoid resistance[J].Hum Mutat,2016,37(8):794-803.DOI:10.1002/humu.23008.
[19] Fleseriu M,Biller BM,Findling JW,et al.Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome[J].J Clin Endocrinol Metab,2012,97(6):2039-2049.DOI:10.1210/jc.2011-3350.
[20] Zhou XE,Suino-Powell KM,Xu Y,et al.The orphan nuclear receptor TR4 is a vitamin A-activated nuclear receptor[J].J Biol Chem,2011,286(4):2877-2885.DOI:10.1074/jbc.M110.168740.
[21] Du L,Bergsneider M,Mirsadraei L,et al.Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease[J].Proc Natl Acad Sci U S A,2013,110(21):8555-8560.DOI:10.1073/pnas.1306182110.
[22] Zhang D,Du L,Heaney AP.Testicular receptor-4: novel regulator of glucocorticoid resistance[J].J Clin Endocrinol Metab,2016,101(8):3123-3133.DOI:10.1210/jc.2016-1379.
[23] Yan ZH,Karam WG,Staudinger JL,et al.Regulation of peroxisome proliferator-activated receptor alpha-induced transactivation by the nuclear orphan receptor TAK1/TR4[J].J Biol Chem,1998,273(18):10948-10957.
[24] Hazel TG,Nathans D,Lau LF.A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily[J].Proc Natl Acad Sci U S A,1988,85(22):8444-8448.
[25] Ranhotra HS. The NR4A orphan nuclear receptors: mediators in metabolism and diseases[J].J Recept Signal Transduct Res,2015,35(2):184-188. DOI:10.3109/10799893.2014.948555.
[26] Philips A,Lesage S,Gingras R,et al.Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells[J].Mol Cell Biol,1997,17(10):5946-5951.
[27] Okabe T,Takayanagi R,Adachi M,et al.Nur77, a member of the steroid receptor superfamily, antagonizes negative feedback of ACTH synthesis and secretion by glucocorticoid in pituitary corticotrope cells[J].J Endocrinol,1998,156(1):169-175.
[28] Martens C,Bilodeau S,Maira M,et al.Protein-protein interactions and transcriptional antagonism between the subfamily of NGFI-B/Nur77 orphan nuclear receptors and glucocorticoid receptor[J].Mol Endocrinol,2005,19(4):885-897.DOI10.1210/me.2004-0333.
[29] Tabuchi Y,Kitamura T,Fukuhara A,et al.Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease[J].Endocr J,2016,63(6):545-554.DOI:10.1507/endocrj.EJ15-0695.
[30] Martinez-Zapien D,Delsuc MA,Travé G,et al.Production and characterization of a retinoic acid receptor RARγ construction encompassing the DNA binding domain and the disordered N-terminal proline rich domain[J].Protein Expr Purif,2014,95:113-120.DOI:10.1016/j.pep.2013.12.001.
[31] Egea PF,Mitschler A,Moras D.Molecular recognition of agonist ligands by RXRs[J].Mol Endocrinol,2002,16(5):987-997.DOI:10.1210/mend.16.5.0823.
[32] Ondkova S,Bakos J,Macejova D,et al.Changes in retinoic acid receptor status, 5'-deiodinase activity and neuroendocrine response to voluntary wheel running[J].Gen Comp Endocrinol,2010,165(2):304-308.DOI:10.1016/j.ygcen.2009.07.012.
[33] Páez-Pereda M,Kovalovsky D,Hopfner U,et al.Retinoic acid prevents experimental Cushing syndrome[J].J Clin Invest,2001,108(8):1123-1131.DOI:10.1172/JCI11098.
[34] Uruno A,Saito-Hakoda A,Yokoyama A,et al.Retinoic acid receptor-α up-regulates proopiomelanocortin gene expression in AtT20 corticotroph cells[J].Endocr J,2014,61(11):1105-1114.
[35] Saito-Hakoda A,Uruno A,Yokoyama A,et al.Effects of RXR agonists on cell proliferation/apoptosis and ACTH secretion/Pomc expression[J].PLoS One,2015,10(12):e0141960.DOI:10.1371/journal.pone.0141960.
[36] Waddington KE,Jury EC,Pineda-Torra I.Liver X receptors in immune cell function in humans[J].Biochem Soc Trans,2015,43(4):752-757.DOI:10.1042/BST20150112.
[37] Maqdasy S,Trousson A,Tauveron I,et al.Once and for all, LXRα and LXRβ are gatekeepers of the endocrine system[J].Mol Aspects Med,2016,49:31-46.DOI:10.1016/j.mam.2016.04.001.
[38] Matsumoto S,Hashimoto K,Yamada M,et al.Liver X receptor-alpha regulates proopiomelanocortin(POMC)gene transcription in the pituitary[J].Mol Endocrinol,2009,23(1):47-60.DOI:10.1210/me.2007-0533.
[39] Hashimoto K,Matsumoto S,Ishida E,et al.Liver X receptor-α/β expression ratio is increased in ACTH-secreting pituitary adenomas[J].Neurosci Lett,2011,494(1):34-37.DOI:10.1016/j.neulet.2011.02.048.
[40] Cho K,Chung JY,Cho SK,et al.Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway[J].Sci Rep,2015,5:8145.DOI:10.1038/srep08145.
[41] 马晶晶,章涛. PPARγ功能与疾病关系研究进展[J].中国药理学通报,2012,28(5): 601-604.DOI:10.3969/j.issn.1001-1978.2012.05.003.
[42] Bogazzi F,Russo D,Locci MT,et al.Peroxisome proliferator-activated receptor(PPAR)gamma is highly expressed in normal human pituitary gland[J].J Endocrinol Invest,2005,28(10):899-904.
[43] Heaney AP,Fernando M,Yong WH,et al.Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas[J].Nat Med,2002,8(11):1281-1287.DOI:10.1038/nm784.
[44] Torres RC,Magalhães NS,E Silva PM,et al. Activation of PPAR-γ reduces HPA axis activity in diabetic rats by up-regulating PI3K expression[J].Exp Mol Pathol,2016,101(2):290-301.DOI:10.1016/j.yexmp.2016.10.002.
[45] Kreutzer J,Jeske I,Hofmann B,et al.No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo[J].Clin Neuropathol,2009,28(6):430-439.
[46] Pecori Giraldi F,Scaroni C,Arvat E,et al.Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease[J].Clin Endocrinol(Oxf),2006,64(2):219-224.DOI:10.1111/j.1365-2265.2006.02452.x.
[47] Ambrosi B,Dall'Asta C,Cannavo S,et al.Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease[J].Eur J Endocrinol,2004,151(2):173-178.
[48] Cannavò S,Ambrosi B,Chiodini I,et al.Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing's disease[J].J Endocrinol Invest,2004,27(5):RC8-RC11.